Company news
Krystal Biotech, Inc. (NASDAQ:KRYS) news
Krystal Biotech, Inc. news releases on 6ix. Latest, Sep 3, 2026: Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference
Press releases & updates
Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference
September 3, 2026
Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results
August 3, 2026
Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026
July 23, 2026
Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600
July 20, 2026
Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
May 18, 2026
Krystal Biotech to Present at BofA Securities 2026 Health Care Conference
May 7, 2026
Krystal Biotech Announces First Quarter 2026 Financial and Operating Results
May 4, 2026
Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026
April 21, 2026
VYJUVEK (Krystal Biotech) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
March 13, 2026
Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference
February 23, 2026
Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results
February 17, 2026
Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
February 10, 2026
Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
February 9, 2026
Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
January 10, 2026
Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis
January 7, 2026
Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis
January 7, 2026
Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference
January 4, 2026
Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference
November 25, 2025
Krystal Biotech Announces Third Quarter 2025 Financial and Operating Results
November 2, 2025
Krystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025
October 20, 2025
Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis
October 13, 2025
Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label
September 14, 2025
Krystal Biotech to Present at Cantor Global Healthcare Conference 2025
September 1, 2025
Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer
August 20, 2025
Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results
August 3, 2025
Krystal Biotech to Report Second Quarter 2025 Financial Results on August 4, 2025
July 28, 2025
Krystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa
July 24, 2025
Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté
July 23, 2025
Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis
July 8, 2025
Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa
June 23, 2025
Krystal Biotech to Present at Goldman Sachs 46th Annual Global Healthcare Conference
June 2, 2025
Krystal Biotech to Present at BofA Securities 2025 Health Care Conference
May 6, 2025
Krystal Biotech Announces First Quarter 2025 Financial and Operating Results
May 5, 2025
Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
April 27, 2025
Krystal Biotech to Present at Upcoming Scientific Conferences
April 23, 2025
Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025
April 16, 2025
Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer
April 6, 2025
Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
February 27, 2025
Krystal Biotech to Present at TD Cowen 45th Annual Health Care Conference
February 25, 2025
Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results
February 18, 2025
Krystal Biotech to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025
February 5, 2025
Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer
January 13, 2025
Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer
December 17, 2024
Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and Increase in Lung AAT to Therapeutic Levels
December 11, 2024
Krystal Biotech Provides Update on EMA’s Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa
December 8, 2024
Krystal Biotech to Present at Upcoming Investor Conferences
November 26, 2024
Krystal Biotech to Present at Stifel 2024 Healthcare Conference
November 11, 2024
Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference
November 5, 2024
Krystal Biotech Announces Third Quarter 2024 Financial Results and Provides Business Updates
November 3, 2024
Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024
October 27, 2024